spacer
home > ebr > summer 2002 > preventing risk becoming a crisis
PUBLICATIONS
European Biopharmaceutical Review

Preventing Risk Becoming a Crisis

Timing has conspired to bring biopharmaceutical companies into the risk transfer arena just as the insurance market is at its least receptive to such risks. This article will highlight the driving factors and the change in management approach needed to negotiate this business hurdle, which will be new to many companies.When two independent industries both undergo radical and fundamental shifts in the make-up of their own revenue base, the results will be dramatic. Such is the current interface between the emerging biopharmaceutical industry and the retrenching insurance industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Howard Pearson, a Director and Head of the Science and Technology Team at The Miller Insurance Group

Howard Pearson is a Director of The Miller Insurance Group, where he heads up the science and technology team.
He is responsible for leading Millers' relationship with the biopharmaceutical industry and the UK Bio Industry Association. Howard holds a Fellowship of the Chartered Insurance Institute and is Chairman of the British Insurance Brokers Association's South East Region.

spacer
Howard Pearson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Trial Supply West Coast Conference 2019

Philadelphia, USA – April 24, 2019. This year’s Clinical Trial Supply West Coast Conference will see leading biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) showcasing its specialist clinical trials expertise in relation to scheduled drugs.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement